We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$177M
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter
Est. Return
+0.36%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$250M
AUM Growth
+$113M
(+82%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
101.74%
Top 10 Holdings %
Top 10 Hldgs %
70.9%
Holding
100
New
34
Increased
20
Reduced
25
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RADX
Radiopharm Theranostics
RADX
|
+$248M |
| 2 |
Tenax Therapeutics
TENX
|
+$13M |
| 3 |
CAMP4 Therapeutics
CAMP
|
+$5.51M |
| 4 |
Verastem
VSTM
|
+$3.52M |
| 5 |
Curis
CRIS
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$3.59M |
| 2 |
Inhibikase Therapeutics
IKT
|
+$2.47M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$2.39M |
| 4 |
Eledon Pharmaceuticals
ELDN
|
+$2.02M |
| 5 |
Edesa Biotech
EDSA
|
+$1.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 54.47% |
| 2 | Healthcare | 45.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zentalis Pharmaceuticals
ZNTL
$387M
| $630K | 0.25% |
269,100
-194,600
| -42% | -$503K |
|
52
Pasithea Therapeutics
KTTA
$19.4M
| $617K | 0.25% |
831,301
+556,239
| +202% | +$465K |
|
|
MSLE
53
Satellos Bioscience
MSLE
$201M
| $563K | 0.23% |
+100,000
| New | +$983K |
|
54
Phathom Pharmaceuticals
PHAT
$765M
| $556K | 0.22% |
+50,010
| New | +$632K |
|
|
OKUR
55
OnKure Therapeutics
OKUR
$141M
| $549K | 0.22% |
+132,578
| New | +$409K |
|
56
Xilio Therapeutics
XLO
$59.9M
| $540K | 0.22% |
64,162
+55,143
| +611% | +$452K |
|
57
Verrica Pharmaceuticals
VRCA
$90.2M
| $528K | 0.21% |
99,735
-253,934
| -72% | -$1.63M |
|
58
Candel Therapeutics
CADL
$969M
| $502K | 0.2% |
+102,500
| New | +$558K |
|
59
CALL
Abeona Therapeutics
ABEO
$341M
| $448K | 0.18% |
100,000
-100,000
| -50% | -$500K |
|
60
Precision Optics
POCI
$48.3M
| $439K | 0.18% |
+100,000
| New | +$458K |
|
|
QNRX
61
Quoin Pharmaceuticals
QNRX
$14.5M
| $353K | 0.14% |
53,460
-24,729
| -32% | -$224K |
|
62
Establishment Labs
ESTA
$2.22B
| $341K | 0.14% |
+6,000
| New | +$410K |
|
|
UPB
63
Upstream Bio Inc
UPB
$333M
| $315K | 0.13% |
+35,000
| New | +$630K |
|
|
IRD
64
Opus Genetics
IRD
$367M
| $313K | 0.13% |
+68,688
| New | +$238K |
|
65
Arvinas
ARVN
$602M
| $292K | 0.12% |
+27,500
| New | +$341K |
|
66
Pliant Therapeutics
PLRX
$71.8M
| $283K | 0.11% |
224,650
-5,400
| -2% | -$6.82K |
|
67
Janux Therapeutics
JANX
$1.23B
| $278K | 0.11% |
20,000
| – | – |
|
68
OmniAb
OABI
$608M
| $258K | 0.1% |
164,045
-536,955
| -77% | -$969K |
|
69
Xeris Biopharma Holdings
XERS
$1.55B
| $232K | 0.09% |
+40,030
| New | +$265K |
|
70
Compugen
CGEN
$246M
| $222K | 0.09% |
104,300
-201,100
| -66% | -$390K |
|
71
Neumora Therapeutics
NMRA
$241M
| $195K | 0.08% |
+100,000
| New | +$259K |
|
72
SAB Biotherapeutics
SABS
$338M
| $192K | 0.08% |
+50,000
| New | +$199K |
|
73
SI-BONE Inc
SIBN
$831M
| $189K | 0.08% |
+14,964
| New | +$234K |
|
|
74
Edesa Biotech
EDSA
$46.8M
| $157K | 0.06% |
30,000
-657,500
| -96% | -$1.97M |
|
75
CNS Pharmaceuticals
CNSP
$8.7M
| $146K | 0.06% |
61,000
+12,173
| +25% | +$50.4K |
|
Similar funds
RP
MSA
HF
BFAG
CWP
MVM
CMP
JESC
Stonepine Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Stonepine Capital Management held 100 positions worth $250M, up 82% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Stonepine Capital Management deployed $254M of net new capital in Q1 2026, opening 34 new positions and adding to 20 existing holdings. Its largest new stake was Sol-Gel Technologies: 27,778 shares worth $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 54% of assets, up from 7.7% a quarter earlier, followed by Healthcare.
On the sell side, the largest reduction was Inhibikase Therapeutics, an estimated $2.47M trimmed.
- Stonepine Capital Management's largest Q1 2026 buy was Sol-Gel Technologies: 27,778 shares worth $2.2M.
- Stonepine Capital Management added most to Radiopharm Theranostics in Q1 2026, an estimated $248M increase.
- Stonepine Capital Management's biggest Q1 2026 reduction was Inhibikase Therapeutics, cutting an estimated $2.47M.
- Stonepine Capital Management fully exited Indivior Pharmaceuticals in Q1 2026, selling an estimated $3.59M.
- Stonepine Capital Management's ten largest holdings make up 71% of its $250M portfolio in Q1 2026.
- Stonepine Capital Management opened 34 new positions and closed 17 in Q1 2026.
- Stonepine Capital Management's portfolio value rose 82% quarter-over-quarter to $250M.
Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.